# Filip Janku

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6282807/publications.pdf

Version: 2024-02-01

| 152 | 12,577 | 34105 | 29157 |
|---|---|---|---|
| papers | citations | 52 h-index | 104 g-index |

| 156 | 156 | 156 | 19425 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291. | 27.6 | 762 |
| 2 | Autophagy as a target for anticancer therapy. Nature Reviews Clinical Oncology, 2011, 8, 528-539. | 27.6 | 709 |
| 3 | Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175. | | 648 |
| 4 | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038. | 1.6 | 583 |
| 5 | Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research, 2012, 18, 6373-6383. | 7.0 | 458 |
| 6 | PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 2012, 30, 777-782. | 1.6 | 414 |
| 7 | Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762. | 1.6 | 372 |
| 8 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165. | 9.4 | 372 |
| 9 | PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 558-565. | 4.1 | 311 |
| 10 | Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299. | 1.6 | 298 |
| 11 | Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses. Science Translational Medicine, 2014, 6, 249ra111. | 12.4 | 285 |
| 12 | First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery, 2018, 8, 184-195. | 9.4 | 283 |
| 13 | A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 730-738. | 7.0 | 265 |
| 14 | PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 2013, 73, 276-284. | 0.9 | 262 |
| 15 | Targeted therapy in non-small-cell lung cancerâ€”is it becoming a reality?. Nature Reviews Clinical Oncology, 2010, 7, 401-414. | 27.6 | 231 |
| 16 | Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Reports, 2014, 6, 377-387. | 6.4 | 210 |
| 17 | Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701. | 0.9 | 203 |
| 18 | Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365. | 9.4 | 192 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology and Oncology, 2015, 8, 58. | 17.0 | 191 |
| 20 | Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treatment Reviews, 2017, 59, 93-101. | 7.7 | 191 |
| 21 | Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research, 2014, 20, 4827-4836. | 7.0 | 186 |
| 22 | Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 2019, 35, 738-751.e9. | 16.8 | 178 |
| 23 | PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769. | 2.5 | 174 |
| 24 | Ivosidenib in Isocitrate Dehydrogenase 1â€“Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406. | 1.6 | 167 |
| 25 | Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720. | 8.1 | 161 |
| 26 | Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509. | 7.1 | 154 |
| 27 | Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology, 2016, 34, 1764-1771. | 1.6 | 149 |
| 28 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646. | 2.6 | 149 |
| 29 | Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1601-1612. | 1.1 | 127 |
| 30 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188. | 7.0 | 127 |
| 31 | Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71. | 9.4 | 115 |
| 32 | Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100. | | 114 |
| 33 | Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499. | 7.0 | 112 |
| 34 | Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precision Oncology, 2017, 2017, 1-18. | 3.0 | 107 |
| 35 | P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget, 2013, 4, 705-714. | 1.8 | 96 |
| 36 | Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347. | | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer, 2012, 118, 1422-1428. | 4.1 | 88 |
| 38 | Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821. | 1.8 | 86 |
| 39 | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology, 2020, 38, 1693-1701. | 1.6 | 86 |
| 40 | BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes. PLoS ONE, 2011, 6, e25806. | 2.5 | 83 |
| 41 | Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget, 2014, 5, 3012-3022. | 1.8 | 82 |
| 42 | PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget, 2012, 3, 1566-1575. | 1.8 | 79 |
| 43 | BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404. | 4.1 | 78 |
| 44 | Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. Journal of Clinical Oncology, 2010, 28, e633-e636. | 1.6 | 77 |
| 45 | Erdheim-Chester Disease: Characteristics and Management. Mayo Clinic Proceedings, 2014, 89, 985-996. | 3.0 | 75 |
| 46 | TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 2475-2485. | 4.1 | 73 |
| 47 | The mu opioid receptor: A new target for cancer therapy?. Cancer, 2015, 121, 2681-2688. | 4.1 | 63 |
| 48 | Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547. | 4.1 | 63 |
| 49 | BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget, 2014, 5, 3607-3610. | 1.8 | 63 |
| 50 | Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget, 2017, 8, 39254-39267. | 1.8 | 62 |
| 51 | Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology, 2020, 38, 3294-3303. | 1.6 | 61 |
| 52 | First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 1237-1246. | 7.0 | 61 |
| 53 | Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 96-106. | 7.0 | 59 |
| 54 | Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors withRAS/RAFAlterations. Oncologist, 2020, 25, e160-e169. | 3.7 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354. | 1.8 | 54 |
| 56 | Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. Expert Review of Molecular Diagnostics, 2015, 15, 1631-1644. | 3.1 | 53 |
| 57 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666. | 7.0 | 53 |
| 58 | Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget, 2014, 5, 11168-11179. | 1.8 | 53 |
| 59 | Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656. | 7.0 | 50 |
| 60 | Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931. | 7.0 | 50 |
| 61 | Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3014-3014. | 1.6 | 50 |
| 62 | FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388. | 2.5 | 50 |
| 63 | A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. Clinical Cancer Research, 2011, 17, 6840-6846. | 7.0 | 47 |
| 64 | A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 407-418. | 2.3 | 46 |
| 65 | Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1300-1309. | 3.7 | 46 |
| 66 | BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894. | 1.8 | 45 |
| 67 | KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. PLoS ONE, 2012, 7, e38033. | 2.5 | 44 |
| 68 | Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531. | 1.8 | 44 |
| 69 | Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics, 2013, 12, 2857-2863. | 4.1 | 42 |
| 70 | Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580. | 2.2 | 42 |
| 71 | KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Research, 2005, 15, 251-256. | 1.2 | 38 |
| 72 | Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers, 2021, 13, 3600. | 3.7 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology and Oncology, 2019, 12, 145. | 17.0 | 35 |
| 74 | Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience, 2016, 3, 164-172. | 2.2 | 34 |
| 75 | Phase I Dose-Escalation Study of Antiâ€“CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Molecular Cancer Therapeutics, 2018, 17, 671-676. | 4.1 | 33 |
| 76 | Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733. | 7.0 | 33 |
| 77 | Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. PLoS ONE, 2014, 9, e93676. | 2.5 | 32 |
| 78 | Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228. | 3.7 | 30 |
| 79 | Nonâ€“Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment. Journal of Thoracic Oncology, 2013, 8, e19-e20. | 1.1 | 29 |
| 80 | A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal. Oncotarget, 2013, 4, 463-473. | 1.8 | 27 |
| 81 | Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157. | 4.1 | 26 |
| 82 | A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational New Drugs, 2015, 33, 177-186. | 2.6 | 25 |
| 83 | Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. Journal of Clinical Oncology, 2018, 36, 2002-2002. | 1.6 | 25 |
| 84 | Associations between the gut microbiome and fatigue in cancer patients. Scientific Reports, 2021, 11, 5847. | 3.3 | 24 |
| 85 | Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications. Oncotarget, 2013, 4, 884-889. | 1.8 | 24 |
| 86 | Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treatment Reviews, 2015, 41, 391-400. | 7.7 | 23 |
| 87 | First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Investigational New Drugs, 2021, 39, 1348-1356. | 2.6 | 22 |
| 88 | Hormonal modulation of ESR1 mutant metastasis. Oncogene, 2021, 40, 997-1011. | 5.9 | 22 |
| 89 | Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Nonâ€“Small Cell Lung Cancer Published between 2000 and 2009. Clinical Cancer Research, 2012, 18, 6356-6363. | 7.0 | 21 |
| 90 | Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963. | 3.3 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience, 2017, 4, 47-56. | 2.2 | 21 |
| 92 | Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444. | 2.8 | 20 |
| 93 | Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific Reports, 2021, 11, 3667. | 3.3 | 20 |
| 94 | Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. European Journal of Cancer, 2021, 155, 236-244. | 2.8 | 19 |
| 95 | Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. JCO Precision Oncology, 2018, 2, 1-11. | 3.0 | 17 |
| 96 | Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587. | 7.0 | 16 |
| 97 | Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. Oncotarget, 2013, 4, 772-784. | 1.8 | 16 |
| 98 | Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administrationâ€“Approved Treatment. Clinical Cancer Research, 2010, 16, 4031-4037. | 7.0 | 15 |
| 99 | Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology, 2022, , . | 3.0 | 15 |
| 100 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2022, 40, 1001-1010. | 2.6 | 14 |
| 101 | Cell-free DNA as a novel marker in cancer therapy. Biomarkers in Medicine, 2015, 9, 703-712. | 1.4 | 13 |
| 102 | Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs, 2015, 33, 700-709. | 2.6 | 12 |
| 103 | Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448. | 3.3 | 12 |
| 104 | Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. Journal of Clinical Oncology, 2016, 34, e34-e37. | 1.6 | 12 |
| 105 | Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3590-3590. | 1.6 | 12 |
| 106 | A Tale of Two Histiocytic Disorders. Oncologist, 2013, 18, 2-4. | 3.7 | 11 |
| 107 | Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer, 2015, 15, 442. | 2.6 | 11 |
| 108 | Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931. | | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget, 2014, 5, 3871-3879. | 1.8 | 11 |
| 110 | Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF â€mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472. | 4.1 | 10 |
| 111 | Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports, 2020, 10, 3080. | 3.3 | 10 |
| 112 | Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology, 2022, 6, e2100197. | 3.0 | 10 |
| 113 | Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270. | 1.8 | 9 |
| 114 | Outcomes of Patients with Advanced Nonâ€Small Cell Lung Cancer Treated in a Phase I Clinic. Oncologist, 2011, 16, 327-335. | 3.7 | 8 |
| 115 | Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 215-224. | 2.6 | 8 |
| 116 | Bringing Blood-Based Molecular Testing to the Clinic. Clinical Cancer Research, 2016, 22, 5400-5402. | 7.0 | 8 |
| 117 | RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. Journal of Cancer, 2020, 11, 3543-3550. | 2.5 | 8 |
| 118 | PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.. Journal of Clinical Oncology, 2012, 30, 10510-10510. | 1.6 | 8 |
| 119 | Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. Journal of Clinical Oncology, 2020, 38, 3640-3640. | 1.6 | 8 |
| 120 | Advances on the BRAF Front in Colorectal Cancer. Cancer Discovery, 2018, 8, 389-391. | 9.4 | 7 |
| 121 | Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402. | 3.4 | 7 |
| 122 | Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. Oncoscience, 2014, 1, 522-530. | 2.2 | 7 |
| 123 | A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. Scientific Reports, 2021, 11, 19653. | 3.3 | 7 |
| 124 | Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports, 2022, 12, . | 3.3 | 7 |
| 125 | Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Targeted Oncology, 2013, 8, 183-188. | 3.6 | 6 |
| 126 | Bringing target-matched PI3King from the bench to the clinic. Cell Cycle, 2013, 12, 1817-1818. | 2.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10. | 3.0 | 6 |
| 128 | Doseâ€escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAFâ€mutated advanced cancers. Cancer, 2021, 127, 391-402. | 4.1 | 6 |
| 129 | The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.. Journal of Clinical Oncology, 2020, 38, 3547-3547. | 1.6 | 6 |
| 130 | Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946. | 1.8 | 6 |
| 131 | Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ˜positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255. | 7.0 | 5 |
| 132 | Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multiâ€arm phase Ib study. Investigational New Drugs, 2021, 39, 1357-1365. | 2.6 | 5 |
| 133 | Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806. | 1.8 | 5 |
| 134 | Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.. Journal of Clinical Oncology, 2020, 38, TPS6590-TPS6590. | 1.6 | 5 |
| 135 | 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bulletin Du Cancer, 2004, 91, E279-83. | 1.6 | 5 |
| 136 | Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement. Irish Journal of Medical Science, 2011, 180, 765-766. | 1.5 | 4 |
| 137 | Castlemanâ€™s disease and sarcoidosis, a rare association resulting in a â€œmixedâ€•response: a case report. Journal of Medical Case Reports, 2015, 9, 45. | 0.8 | 4 |
| 138 | Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. Journal of Clinical Oncology, 2020, 38, 2504-2504. | 1.6 | 4 |
| 139 | Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq1 1 0.784314 | 4.4 | 3 |
| 140 | A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3162-TPS3162. | 1.6 | 3 |
| 141 | Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?. Journal of Clinical Oncology, 2012, 30, 892-893. | 1.6 | 2 |
| 142 | Circulating tumor DNAâ€”From bench to bedside. Current Problems in Cancer, 2017, 41, 212-221. | 2.0 | 2 |
| 143 | Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precision Oncology, 2018, 2, 1-19. | 3.0 | 2 |
| 144 | Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncology, 2018, 4, 1788. | 7.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors. , 2019, , . | | 2 |
| 146 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids. Oncoscience, 2019, 6, 296-297. | 2.2 | 1 |
| 147 | Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24. | 1.9 | 1 |
| 148 | Abstract 3514: A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway.. , 2013, , . | | 1 |
| 149 | Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.. Journal of Clinical Oncology, 2020, 38, e15223-e15223. | 1.6 | 0 |
| 150 | An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.. Journal of Clinical Oncology, 2020, 38, 6085-6085. | 1.6 | 0 |
| 151 | Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy.. Journal of Clinical Oncology, 2020, 38, 3533-3533. | 1.6 | 0 |
| 152 | Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247. | | 0 |